Cargando…

Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism

OBJECTIVE: To investigate the effect and mechanism of blocking the signaling pathways of the T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) and programmed death protein 1 (PD-1) in dendritic cell-cytokine induced killer (DC-CIK) cells on human lung adenocarcinoma A549 cells. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Liang, Chen, Qijiu, Chen, Hui, Wang, Li, Zhang, Jianyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357700/ https://www.ncbi.nlm.nih.gov/pubmed/35958924 http://dx.doi.org/10.1155/2022/4097576

Ejemplares similares

Antiprogramed cell death‐1 therapy with microspheres for metastatic liver tumors
por: Kamimura, Hiroteru, et al.
Publicado: (2019)

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
por: Liu, Guiyuan, et al.
Publicado: (2022)

Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: A case report
por: Huang, Shao M., et al.
Publicado: (2023)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)

Comparative investigation of the effects of specific antigen-sensitized DC-CIK and DC-CTL cells against B16 melanoma tumor cells
por: Ren, Peng-Tao, et al.
Publicado: (2017)

The possible molecular regulation mechanism of CIK cells inhibiting the proliferation of Human Lung Adenocarcinoma NCL-H157 Cells
por: Li, Dengrui, et al.
Publicado: (2016)

Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies
por: Minami, Hironobu, et al.
Publicado: (2020)

Sideroflexin1 as a novel tumor marker independently predicts survival in lung adenocarcinoma
por: Chen, Qijiu, et al.
Publicado: (2019)

Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
por: Yang, Liu, et al.
Publicado: (2021)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

Killing effects of Huaier Granule combined with DC-CIK on nude mice transplanted with colon carcinoma cell line
por: Sun, Wen-Wen, et al.
Publicado: (2017)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
por: Jo, Hitomi, et al.
Publicado: (2023)

The epistemic culture in an online citizen science project: Programs, antiprograms and epistemic subjects
por: Kasperowski, Dick, et al.
Publicado: (2018)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Stimulation of DC-CIK with PADI4 Protein Can Significantly Elevate the Therapeutic Efficiency in Esophageal Cancer
por: Liu, Chunyan, et al.
Publicado: (2019)

Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma
por: Gan, Yi-Xiu, et al.
Publicado: (2022)

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
por: Huang, Jumin, et al.
Publicado: (2022)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Identification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody
por: Zhang, Dong, et al.
Publicado: (2020)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
por: Wang, Ying, et al.
Publicado: (2015)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

DC-CIK biotherapy for a recurrent benign lymphoepithelial lesion of the salivary gland: A case report and literature review
por: XING, DEJUN, et al.
Publicado: (2014)

Comparative Proteomic Analysis of Lysine Acetylation in Fish CIK Cells Infected with Aquareovirus
por: Guo, Hong, et al.
Publicado: (2017)

Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill
por: Mohan, Vishnu, et al.
Publicado: (2021)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals
por: Ryser, Stefan, et al.
Publicado: (2017)

CD300LG improves the cytotoxic activity of CIK
por: Wang, Qiuyue, et al.
Publicado: (2017)

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
por: Dayoub, Adam S., et al.
Publicado: (2020)

The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials
por: Xiao, Zheng, et al.
Publicado: (2018)

DC‐CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1‐ASK1‐AIP1 pathway to kill autologous ovarian cancer stem cells
por: Qin, Wenxing, et al.
Publicado: (2018)

Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
por: Naderi-Azad, Sheida, et al.
Publicado: (2020)

Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice
por: Boutsikou, Efimia, et al.
Publicado: (2018)

Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
por: Zhao, Qun, et al.
Publicado: (2010)

Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures
por: Greenlee, John E, et al.
Publicado: (2014)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

The destiny of the resistance/susceptibility against GCRV is controlled by epigenetic mechanisms in CIK cells
por: Shang, Xueying, et al.
Publicado: (2017)

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
por: Sharma, Amit, et al.
Publicado: (2021)

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
por: Kuang, Zhihui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i57j8fke9g7mbetq9pci2n1sht